Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 3Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 6Carboplatin 3valrubicin 2Cisplatin 2vinflunine 1toripalimab 1pertuzumab 1disitamab vedotin 1cabazitaxel 1apaziquone 1XRP6258 1Watchful Waiting 1Vinblastine 1Trastuzumab 1Transurethral Resection of Bladder 1Tranexamic Acid 1Saline Solution 1RC48 antibody 1Oncolytic Virotherapy 1Mitomycin 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lapatinib 1Interferons 1Interferon-alpha 1Gabapentin 1Circulating Tumor DNA 1Celecoxib 1BCG Vaccine 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Urinary Bladder Neoplasms × vinflunine × Clear all
NCT00389155 2015-12-07

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Bristol-Myers Squibb

Phase 2/3 Completed
34 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡